摘要
目的探讨多西他赛联合奈达铂、氟尿嘧啶治疗复发晚期食管癌的临床效果。方法将80例复发晚期食管癌患者根据信封法随机平分为治疗组与对照组,各40例。对照组给予常规化疗,治疗组给予多西他赛联合奈达铂、氟尿嘧啶化疗,每3周为1个疗程,共化疗2个疗程。对2组患者近期疗效、不良反应、生活质量及生存情况进行比较。结果治疗组的有效率为75.0%,对照组的有效率为57.5%,治疗组的近期疗效明显好于对照组(P<0.05)。治疗组的血液毒性、消化系统反应、食管炎、肺炎等不良反应发生例数与分级都明显低于对照组(P<0.05)。治疗组的疲劳、疼痛、恶心呕吐评分都明显低于对照组(P<0.05)。治疗组与对照组的中位生存时间分别为(19.33±2.78)个月和(14.98±3.14)个月,差异有统计学意义(P<0.05)。结论多西他赛联合奈达铂、氟尿嘧啶治疗复发晚期食管癌能减少化疗不良反应,减轻临床症状,提高综合治疗效果,提高患者的生活质量,延长患者的生存时间。
Objective To investigate the clinical effects of docetaxel combined with nedaplatin,fluorouracil in the treatment of recurrent advanced gastrointestinal cancer. Methods 80 recurrent advanced esophageal cancer were randomly divided into the treatment group and the control group,each with 40 patients,the control group received conventional chemotherapy,the treatment group received docetaxel combined with nedaplatin,fluorouracil chemotherapy,every 3 weeks was a course of treatment,the total were 2 courses of chemotherapy. Then the short-term effects,toxicity,life quality and survival situation were compared.Results The effective rates were 75. 0% and 57. 5% in the treatment group and the control group,the effective rate in the treatment group was significantly better than that of the control group( P〈0. 05). The number of cases with hematologic toxicity,digestive reaction,esophagitis,pneumonia in the treatment group was significantly lower than that of the control group( P〈0. 05).Fatigue,pain,nausea and vomiting scores in the treatment group were significantly lower than those of the control group( P〈0. 05). The median survival time in the treatment group and the control group were 14. 98 ± 3. 14 months and 19. 33 ± 2. 78months( P〈0. 05). Conclusion Docetaxel combined with nedaplatin,fluorouracil in the treatment of recurrent advanced esophageal cancer can reduce side effects of chemotherapy,reduce clinical symptoms,improve the overall therapeutic effect and quality of life,and prolong survival time.
出处
《实用癌症杂志》
2016年第5期778-780,783,共4页
The Practical Journal of Cancer
关键词
多西他赛
奈达铂
氟尿嘧啶
食管癌
生活质量
Docetaxel
Nedaplatin
Fluorouracil
Esophageal cancer
Quality of life